Archive With 76.1m HIV-positive and 35m dead, optimism greets AIDS...

With 76.1m HIV-positive and 35m dead, optimism greets AIDS vaccine test

-

- Advertisment -

The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

Tested in 393 people in the United States, Rwanda, Uganda, South Africa and Thailand, the drug “raised antibody responses in 100 percent of vaccine recipients,” Dan Barouch, a member of the research team, said in Paris.

“These promising … data, together with advances from many other investigators in the field, support a new sense of optimism that development of an HIV vaccine might in fact be possible,” he told journalists at an HIV science conference organised by the International AIDS Society.

A vaccine is widely considered the best way of ending an epidemic that has seen 76.1 million people infected with HIV, the virus that causes AIDS, since the early 1980s.

Some 35 million have died.

Last year alone, 1.8 million people around the world were newly infected, according to UNAIDS, and there were 36.7 million people living with the virus.

Of those, 19.5 million had access to virus-suppressing anti-retroviral treatment.

“The ultimate control of the worldwide HIV epidemic will likely require the development of a safe and effective vaccine,” said Barouch, director of the Centre for Virology and Vaccine Research at the Beth Israel Deaconess Medical Centre in Massachusetts.

“But to date, only four vaccine concepts have been tested for clinical efficacy in the 35-year history of the epidemic.”

The team hopes their prototype will get approval for the next trial phase.

The vaccine uses a common cold virus to deliver antigens — foreign substances that induce the recipient’s immune system to produce intruder-fighting antibodies.

The vaccine is boosted with a protein that raises antibody levels.

In an earlier trial, the prototype prevented infection in 66 percent of rhesus lab monkeys, said Barouch.

In humans, it has now been shown to be safe and to generate an immune response.

“Of course, we don’t know yet whether this vaccine will protect humans,” the researcher said.

“However, these data, to date, support the advancement of this vaccine candidate into a larger … efficacy trial, which we hope will start before the end of this calendar year.”

That will depend on additional data to be gathered in the coming months.

IAS president, Linda-Gail Bekker, described the results as “important news.”

Condoms are still at the front line of efforts to prevent infection — mainly through sex and blood contact.

Director of the National Institute of Allergy and Infectious Diseases in Maryland, Anthony Fauci, told AFP that developing a vaccine was “going to be very difficult” but “would be really a game changer.”

“If in fact, we get a very moderately-effective, a 50-60 percent effective vaccine, that will go a long way when you combine it together with other prevention modalities… to really having a major impact on the pandemic,” he said, ahead of the conference.

Another vaccine candidate, dubbed HVTN 702, is being tested in a major clinical trial in South Africa.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

Gates Foundation’s Annual Goalkeepers Report Finds Stark Disparities in COVID-19 Impacts

...New data reveals world stepped up to prevent worst-case scenarios from happening; spotlights need for long-term investments to ensure...

Op-ed: Africa Should Rethink Business Models for Impact and Sustainability

By Babatunde Oyateru | Corporate Identity Crisis It is no secret that humans anthropomorphise everything; perhaps it is down to the...

We Need to Strategise to Address Emerging Security Threats — Gbajabiamila

...says House ready to do more despite successes recorded The Speaker of the House of Representatives, Rep. Femi Gbajabiamila, has...

Paradigm Initiative, EiE Nigeria, MRA, SERAP Condemn the Continuous Twitter Ban in Nigeria by the Federal Government.

Nigeria’s Twitter ban hits 100 days on Sunday, September 12th, 2021. A milestone leaving the civil society, frontline actors...

USAID Commits $452m to Foster Media, CSO Engagements, Selects Pact, IREX, others

USAID has chosen Pact, along with IREX and our consortium partners, to lead two new regional programs, each titled Civil Society...

Serene Early-TROBB Concepts To Mark Third Anniversary, Trains Teenagers in Vocational Skills

Serene EARLY-TROBB Concepts will be organizing a One-day conference for teenagers and young adults on Mental Health and Menstrual...

Must read

Gates Foundation’s Annual Goalkeepers Report Finds Stark Disparities in COVID-19 Impacts

...New data reveals world stepped up to prevent worst-case...

We Need to Strategise to Address Emerging Security Threats — Gbajabiamila

...says House ready to do more despite successes recorded The...
- Advertisement -

You might also likeRELATED
Recommended to you

%d bloggers like this: